Introduction
The insulin-like growth factors I and II (IGF-I and -II), their receptors and binding proteins constitute a family of cellular modulators that play essential roles in the regulation of metabolism, growth and development. The insulin-like and cell-proliferative effects of the IGFs are mediated by the IGF-I and insulin receptor (1) . The role of the mannose 6-phosphate (M6P)/IGF-II receptor for transport of lysosomal enzymes and for binding and internalization of IGF-II has been well characterized; however, its role in signal transduction in response to IGF-II is still under debate (2, 3) . The biological actions of the IGFs are modulated by specific IGF-binding proteins (IGFBPs), which not only regulate bioavailability of the circulating growth factors but can also inhibit or enhance the actions of IGFs on cells (4) (5) (6) . So far, six distinct high affinity IGFBPs have been identified that differ in molecular mass, binding properties for IGFs and post-translational modifications such as phosphorylation and glycosylation (7) . Abundance of IGFBPs can be regulated at the level of gene expression as well as by limited proteolytic processing (8) .
The proliferation and differentiation of malignant cell systems involve the autocrine secretion of growth factors. Among these, the IGFs play an increasingly recognized role being implicated in tumor formation, growth and metastasis in vivo. These growth factors may reach tumor sites either through the circulation, or may be produced by tumors themselves as well as by adjacent stromal tissue thereby acting as endocrine, paracrine or autocrine growth factors (9, 10) . For the liver, IGF-II has been regarded as a candidate growth factor playing a role in hepatic carcinogenesis. Increased IGF-II gene expression was noted in liver tumors and precursor lesions (altered hepatic foci) in chemically induced hepatocarcinoma of rats (11) , during SV40 T Ag-induced hepatocarcinogenesis in transgenic mice (12, 13) as well as during chronic hepatitis virus infection in woodchucks (14, 15) . In addition, IGF-II transgenic mice showed an increased frequency of hepatocellular carcinomas (HCCs) and lymphomas (16) . On the other hand, transgenic mice homozygous for a disruption of the IGF-II gene developed tumors with reduced malignancy and a higher rate of apoptosis (17) . Notably, in human HCCs, overexpression of IGF-II and re-appearance of fetal IGF-II transcripts have been reported (18) . Expression of the IGF-I receptor (IGF-IR) in HCCs has received less attention. Of note, increased IGF-IR expression has been demonstrated for human hepatoma as well as for fetal and regenerating rat liver (19) . The present study was conducted to determine the potential role of IGFs, of type I and II IGF receptors, of IGFBPs as well as of IGFBP proteases in the regulation of proliferation of the human hepatoma cell line PLC. were iodinated by the chloramin-T method to a specific activity of~60-80 µCi/µg. Recombinant human non-glycosylated IGFBP-3 (rhIGFBP-3) was a gift of Drs A.Sommer and C.Maack (Celtrix, Santa Clara, CA) and was labeled with Na[ 125 I] using IODO-GEN (Pierce, Rockford, IL) to specific activities of 30-60 µCi/µg as described (20) . Chemicals were reagent grade and obtained from commercial sources as indicated: Dulbecco's modified Eagle's medium (DMEM; Biochrom KG, Berlin, Germany); fetal calf serum (FCS), Pefabloc SC (Boehringer Mannheim, Mannheim, Germany); bovine serum albumin (BSA) and antibiotics (Serva Feinbiochemica, Heidelberg, Germany); porcine insulin, hydrocortisone, collagenase, pepstatin A, E64 (Sigma, Deisenhofen, Germany); human growth hormone (GH; Nordisk, Mainz, Germany); enhanced chemiluminescence (ECL) detection kit (Amersham-Buchler), nick translation kit (Life Technology, Eggenstein, Germany); T7 Quick prime kit (Pharmacia, Uppsala, Sweden). Antibodies Polyclonal rabbit antibodies against human IGFBP-1, -2, -3 and -4 were purchased from UBI (Lake Placid, NY). Biotinylated mouse monoclonal antibodies against rabbit IgG were supplied by Dianova (Hamburg, Germany) and horseradish peroxidase-conjugated streptavidin by Zymed Laboratories (San Francisco, CA). A polyclonal antiserum against human placental cathepsin D was raised in rabbits (20) . cDNA probes The following complementary DNA (cDNA) probes were used for northern blot analysis: a 1.5 kb fragment of human IGFBP-1 cDNA, a 1.4 kb fragment of human IGFBP-2 cDNA, a 2.3 kb fragment of human IGFBP-3 cDNA and a 2 kb fragment of IGFBP-4 cDNA (21) were kindly provided by Dr J.Zapf (Zürich, Switzerland) and a 2.8 kb fragment of human IGF-IR cDNA clone p igfr 85 (22) by Dr A.Gray (South San Francisco, CA). cDNAs coding for human IGF-I and for human IGF-II (23) were donated by Dr G.Bell (Chicago, IL), and a cDNA specific for human IGF-IIR by Dr W.Sly (St Louis, MO). Cell culture PLC cells were maintained in DMEM supplemented with 10% (v/v) FCS and passaged three times a week at split ratios of 1:2. Confluent cell cultures grown on 35 mm dishes (Becton Dickinson Labware, Lincoln Park, NJ) were changed to serum-free medium for 12 h prior to the addition of IGF-I, IGF-II, insulin or GH at various concentrations (0.1-100 nmol/l). Incubations continued for 24-72 h as indicated for individual experiments. Cells and media were then collected and stored frozen until assayed. Isolation and culture of human hepatocytes Human liver tissue was obtained from three adult patients treated surgically for solitary liver metastasis in accordance with the regulations with the local Ethical Commitee. Isolation and culturing of human hepatocytes were performed as described previously (24, 25) . Cultures were repetitively evaluated for the presence of contaminating cells by immunocytochemical studies showing negative results for desmin, alpha-smooth muscle actin and no reactivity with the macrophage-specific monoclonal antibodies ED1 and ED2. Vitamin A autofluorescence was negative (data not shown). Human HCC tissue Liver tissue was obtained from two groups of patients, e.g. normal liver tissue from patients undergoing partial hepatectomy for single hepatic metastasis of colorectal carcinomas and HCC tissue from livers removed at the time of liver transplantation. Liver specimens were immediately washed in 0.9% (w/v) NaCl, snap-frozen in liquid nitrogen, and stored at -80°C until assayed. The protocol was approved by the Ethics Committee of the Georg-AugustUniversity Göttingen.
Materials and methods

Materials
Binding studies
After washing PLC cells with DMEM containing 0.2% (w/v) BSA and 2 mmol/l (w/v) lactate (binding buffer), binding studies with [ 125 I]IGF-I and -II were performed as described by Fleig et al. (26) . Cells were preincubated with binding buffer for 1 h at 37°C followed by the addition of radiolabeled IGF-I or -II (10 000 c.p.m./dish) with and without unlabeled IGF-I, IGF-II or insulin in concentrations ranging from 0.01 to 100 nmol/l. After incubation for 6 h at 4°C and centrifugation, supernatants were precipitated with trichloroacetic acid (TCA) to correct for ligand degradation. Cells were washed three times with 0.9% (w/v) NaCl, solubilized in 0.1% (w/v) sodium dodecyl sulfate (SDS) and analyzed for TCA-soluble and -insoluble radioactivity to estimate cell-associated degradation of the ligand. 
Determination of IGF-I and -II
Conditioned media (CM; 72 h, 10 ml) from PLC cells were lyophilized and resuspended in 100 µl of distilled water. For determination of the amount of secreted IGFs, CM were analyzed by commercially available ELISAs (Active IGF-I-ELISA, Active IGF-II-ELISA; DSL, Sinsheim, Germany) according to the instructions of the supplier.
Detection of IGFBPs by western ligand-and immunoblotting
Western ligand blots were performed with [ 125 I]IGF-I according to Hossenlopp et al. (27) with slight modifications as described recently (28) . Detection of IGFBPs by immunoblotting was performed as reported previously (25) .
Isolation of total RNA and northern blot analysis
Total RNA from PLC cells and human hepatocytes was isolated, sizefractionated on a 2% (w/v) agarose gel and transferred to nylon membranes (Amersham-Buchler) as described (25) . In brief, nylon membranes were prehybridized for 2 h at 68°C with hybridization solution (QuikHyb; Stratagene, Heidelberg, Germany) and were then hybridized with [ 32 P]dCTP-labeled cDNA probes at 68°C for 2 h. Thereafter, membranes were washed in standard saline citrate (SSC) with different stringencies, dried and exposed at -80°C to X-ray films (X-Omat AR, Kodak). The cDNA probes for human IGFBPs and IGFs were radiolabeled by random priming and cDNAs for human IGF receptors by nick translation.
Cell-free IGFBP-3 protease assay IGFBP-3 protease assay was performed as described recently (29) . Briefly, [ 125 I]rhIGFBP-3 (~30 000 c.p.m.) were added to 50 µl of conditioned media, adjusted to the indicated pH and incubated at 37°C for 20 h. Samples were solubilized and subjected to SDS-PAGE [12. 5% (w/v) polyacrylamide] under non-reducing conditions. Radiolabeled rhIGFBPs and/or proteolytic fragments were detected by autoradiography. Molecular masses were estimated by comparing the electrophoretic mobility of the IGFBPs and their proteolytic fragments to prestained rainbow markers (Amersham-Buchler).
Immunodepletion of cathepsin D PLC cell medium samples (350 µl) were incubated for 16 h at 4°C with an antiserum directed against human cathepsin D (20 µl) or rabbit preimmune serum (20 µl) preabsorbed to protein-A-sepharose (Sigma). The immune complexes were collected by centrifugation and the supernatants were tested for IGFBP-3 protease activity at pH 4.0 as described above.
Endocytosis of IGFBP-3
PLC cells were incubated at 37°C in DMEM containing [ 125 I]rhIGFBP-3 (~75 000 c.p.m./600 µl) at pH 7.4 for 2-6 h as indicated. Thereafter, an aliquot of 50 µl was taken from the media and processed for SDS-PAGE (12.5% polyacrylamide) under non-reducing conditions. Detection of radiolabeled rhIGFBPs and/or proteolytic fragments by autoradiography was performed as described above.
Cell proliferation IGF-stimulated cell proliferation was assessed by incorporation of [ 3 H]-thymidine as described previously (30) . In brief, PLC cells kept under serumfree conditions for 1 h were incubated with 1 µCi 
Statistical analysis
All experiments were replicated three to four times, and representative autoradiograms are shown. Autoradiographs of ligand-and northern blots were scanned using a laser densitometer (Epson GT-8000, Biometra, Göttingen, Germany). The relative densities of bands were expressed as a percentage of control and as means Ϯ SEM of at least three independent experiments.
Results
mRNA expression of IGF-I and -II
Northern blot analysis of total RNA from PLC cells showed no hybridization with either the IGF-I-or the IGF-II-specific cDNA, even after prolonged exposure. In total RNA from human hepatocytes transcripts for IGF-I were detected (at 7.4, 2.0, 1.6 and 1.0 kb), but not for IGF-II (Figure 1 ). Total RNA extracted from surgically resected normal human liver and human HCC used as control showed both hybridization bands for IGF-I, while transcripts for IGF-II (at 5.3, 2.0, 1.6 and 1.0 kb) were only detected in HCC (Figure 1) .
Using ELISAS for IGF-I and -II, IGF-I and -II peptides in media from PLC cells conditioned for 72 h were below the detection limits of the respective assay (data not shown). 
Expression of IGF-IR and -IIR
Northern blot analysis revealed expression of IGF-IR mRNA at 11 and 7 kb in PLC cells, but not in human hepatocytes (Figure 2 ). IGF-IIR transcripts at 9 kb were detected in PLC cells and in human hepatocytes at about the same level (Figure 2) .
The presence of type I and II IGF receptors on the surface of PLC cells was assessed by binding studies of radiolabeled IGF-I and -II in the presence and absence of increasing concentrations of the unlabeled ligand. Approximately 10% of total radioactivity was cell-associated after incubation with both labeled IGF-I and -II. No degradation of the ligand was observed. Half-maximal binding occurred at IGF-I concentrations of~0.5 nmol/l and at IGF-II concentrations of 1 nmol/l, respectively (data not shown). Addition of insulin in concentrations up to 100 nmol/l resulted in a displacement of labeled IGF-I and -II of only 30.8 Ϯ 1% and 39.0 Ϯ 5.4%, respectively.
In a second approach, the specifity of [ 125 I]IGF-I binding to PLC cell surface receptors was examined by affinity cross- PLC cell conditioned media was 24 Ϯ 8.1% and 8.6 Ϯ 1.2% (mean Ϯ SD), respectively, relative to IGFBP-1 (which was set at 100%) as determined after densitometric analysis of ligand blots from six independent experiments.
Effects of IGF-I and -II on IGFBP biosynthesis
When PLC cells were incubated in the presence of 0.1-100 nmol/l IGF-I or -II for 72 h, IGFBP-3 protein levels in CM increased in a dose-dependent manner as demonstrated by [ 125 I]IGF-I ligand-and immunoblotting ( Figure 5 ). IGF-I and -II at a concentration of 100 nmol/l increased IGFBP-3 abundance 4.7 Ϯ 1.5-fold and 4.3 Ϯ 0.8-fold, respectively, as determined after densitometric analysis of three independent experiments. Both peptides did not affect the level of IGFBP-1, -2 and -4 ( Figure 5 ). Addition of insulin or GH at concentrations up to 100 nmol/l did not alter abundance of IGFBP-1, -2, -3 and -4 in CM of PLC cells (Figure 6 ) as demonstrated by ligand-and immunoblotting. Northern blot analysis demonstrated that IGF-I and -II both stimulated IGFBP-3 mRNA expression in PLC cells dosedependently ( Figure 7 ). IGFBP-3 mRNA level was increased by the addition of 100 nmol/l IGF-I and -II (2.4 Ϯ 0.4-fold and 2.0 Ϯ 0.1-fold, respectively, as compared with the control after densitometric analysis of three independent experiments). The levels of IGFBP-1 and -4 coding mRNA transcripts were not altered by IGF-I or -II. Gene expression of IGFBP-1, -2, -3 and -4 was not affected by insulin or GH in concentrations up to 100 nmol/l (data not shown).
Since IGF-stimulated IGFBP-3 protein levels may either be the result of an increased IGFBP-3 de novo synthesis or an increased release of cell surface associated IGFBP-3, PLC cells were conditioned in the presence of 0.1 mmol/l cycloheximide, a potent inhibitor of translation. Time-course experiments demonstrated that 100 nmol/l IGF-I increased the amount of IGFBP-3 in CM from PLC within 24 h of incubation. When PLC cells were incubated with 100 nmol/l IGF-I in the presence of cycloheximide, secretion of IGFBP-3 was markedly decreased (data not shown). These results indicate that IGF-I affects the biosynthesis rather than the release of cell surfaceassociated IGFBP-3.
IGFBP-3 proteolysis
Since it has been demonstrated that specific proteases are important regulators of IGFBP levels, CM from PLC cells were analyzed for the presence of protease activity against iodinated human IGFBP-3 in a cell-free assay. No fragmentation of rhIGFBP-3 was observed at neutral pH. However, the 30 kDa rhIGFBP-3 was fragmented at pH 4.0 to a major fragment of~23 kDa (Figure 8 ). Little or no proteolysis occurred during incubation in unconditioned media neither at acidic nor at neutral pH. In a pH profile experiment of CM from PLC cells, proteolysis was maximal between pH 3.5 and 4.5 (data not shown). Proteolysis of IGFBP-3 was partially reduced in CM from PLC cells incubated with 100 nmol/l IGF-I or -II when compared with CM of untreated PLC cells as well as to PLC cells kept at 0.1 nmol/l IGF-I or -II ( Figure  8 ). Proteolytic activity was completely inhibited in the presence of the aspartyl protease inhibitor pepstatin A (200 µmol/l) while the serine protease inhibitor Pefabloc (2 mmol/l), the cysteine protease inhibitor E 64 (5 µmol/l) and the chelator EDTA (2 mmol/l) did not affect protease activity (data not shown) indicating the involvement of aspartyl proteases, presumably of cathepsin-D, in acid-activated degradation of IGFBP-3. Immunodepletion of cathepsin D from PLC cell derived media reduced IGFBP-3 proteolysis almost completely ( Figure 9 ). The remaining proteolytic activity was completely abolished by addition of pepstatin A (Figure 9) . When PLC cells were incubated for up to 6 h at 37°C in the presence of [ 125 I]rhIGFBP-3, the intact 30 kDa IGFBP-3 disappeared continuously from the medium while~14 kDa proteolytic fragment could be detected (Figure 10) . The presence of 100 nmol/l IGF-I strongly diminished the degradation of rhIGFBP-3 after 2, 4 and 6 h of incubation, respectively. These data suggest that cell-associated proteases mediated the degradation of IGFBP-3 which was protected in the presence of IGF-I.
Cell proliferation
To investigate the effect of exogenous IGF-I and -II on DNA synthesis in PLC cells, [ 3 H]thymidine incorporation into DNA The most striking differences between human hepatocytes and PLC cells studied in the present paper were the secretion of large amounts of IGF-I peptide and the absence of IGF-IR expression in human hepatocytes. It can be speculated that the lack of the IGF-IR represents an autoregulatory mechanism that protects hepatocytes from the autocrine metabolic and mitogenic effects of IGFs. In contrast, PLC cells were IGF-I mRNA and peptide negative while functionally active IGFIRs were expressed on their cell surface. The relative overexpression of the IGF-IR in PLC cells most probably resulted in ligand-dependent stimulation of cell proliferation as observed in the present study.
The IGF-IR has been implicated in mediating most of the mitogenic effects of both IGF-I and -II (35) and in playing a crucial role in cell proliferation in at least three different ways: (i) it is mitogenic; (ii) it is required in several types of cells for the establishment and maintenance of the transformed phenotype and for tumorigenesis; and (iii) it protects tumor cells from apoptosis, both in vivo and in vitro (36) .
From the present data, IGF-dependent regulation of IGFBP-3 occurred at least in part at a transcriptional level because IGFBP-3 mRNA expression correlated with the amount of secreted protein. In an attempt to define additional posttranscriptional mechanisms of IGFBP-3 regulation, a release of membrane-associated IGFBP-3 in response to IGF-I or -II was excluded. Since limited proteolytic processing of IGFBPs 2126 by proteases has been reported for a number of different cell lines and tissue extracts, CM from PLC cells were tested for protease activity in a cell-free assay using iodinated recombinant human IGFBP-3. In these experiments, no fragmentation of rhIGFBP-3 was observed at physiological pH while for optimal proteolysis an acidification of the CM to pH between 3.5 and 4.5 was necessary. The pH optimum as well as the inhibition of protease activity by pepstatin A, an inhibitor of lysosomal aspartyl proteases, led to the assumption that cathepsin D might be responsible for acid-activated proteolysis either directly or indirectly by activation of IGFBP proteases. When cathepsin D was immunodepleted from CM of PLC cells, IGFBP-3 protease activity was almost completely abolished. This result confirms other studies reporting the involvement of cathepsin D in acid-activated IGFBP-3 proteolysis in CM from human cell lines (37, 38) . However, it remains unclear whether the tumor cell-mediated acidification of the extracellular environment (39, 40) is sufficient to activate secreted procathepsin D. On the other hand, an acidic pH is usually attained in the endosomal, cathepsin D-containing recycling compartment (41) or in lysosomes. To evaluate this possibility, PLC monolayers were incubated at pH 7.4 and 37°C in the presence of iodinated IGFBP-3. The subsequent analysis of the medium revealed the time-dependent disappearance of intact IGFBP-3 and the generation of IGFBP-3 proteolytic fragments of~14 kDa. Since IGFBP-3 cleavage in the presence of PLC cells could be inhibited by pepstatin A, it appears likely that cathepsin D-mediated proteolysis of IGFBP-3 occurred in intracellular organelles followed by partial recycling and release of IGFBP-3 fragments of 14 kDa into the extracellular medium. The failure to detect the intermediate 23 kDa IGFBP-3 proteolytic fragment may be explained by sorting mechanisms favoring the recycling of the 14 kDa fragment. Alternatively, the cell-associated degradation of the 14 kDa IGFBP-3 fragment is the rate-limiting step and results in the fast proteolytic processing of the 23 kDa fragment. Furthermore, the disappearance of intact IGFBP-3 accompanied by an increase in trichloroacetic acid-soluble radioactivity in the medium during the incubation period (T.Braulke, unpublished data) suggests that IGFBP-3 is totally degraded in the presence of PLC cells leading to proteolytic fragments not detectable by SDS-PAGE. It is likely that various proteases are involved in this final degradation process while their subcellular localization has to be determined.
The inhibitory effect of IGF-I on cell-mediated IGFBP-3 proteolysis may result from competition because IGF-I and -II have been shown to be substrates of cathepsin D in vitro (42) . Of interest, cathepsins seem to play a role in the regulation of cellular IGF during tumor growth and invasion. Cathepsin D has been reported to be secreted in larger concentrations by human breast cancer cells than by normal mammary cells and has been considered a potential marker of breast cancer metastases (43) . Increased plasma cathepsin D concentration has been detected in patients with hepatocellular carcinoma as well (44) .
Enhanced stimulation of PLC cell proliferation by [Q 3 A 4 Y 15 L 16 ]IGF-I suggested an inhibitory effect of endogenous IGFBPs in supernatants from PLC cells. Since IGFBP-3 was the only IGFBP that increased after IGF treatment, IGFBP-3 might be responsible for counter-regulation of IGF-induced PLC proliferation. Other studies have reported that IGFBP-3 can both inhibit or enhance cellular actions of IGFs. These apparently contradictive actions of IGFBP-3 may be explained not only by different cell culture systems, but also by the ability of IGFBP-3 to be present in both soluble and membraneassociated forms (45) . Soluble IGFBP-3 inhibits IGF-I action by sequestering the growth factor and preventing its interaction with the receptor while membrane-bound IGFBP-3 has been proposed to potentiate IGF action under certain circumstances (45) . In the cell model presented here, cell-derived soluble IGFBP-3 could act as a buffer, restricting IGF-I binding and action within the limits of its buffering capacity. However, it has recently been demonstrated that different IGFBP-3 proteolytic fragments may both enhance or inhibit cell proliferation independent of IGF-I (46, 47) . Thus, it seems likely that IGF-I-stimulated IGFBP-3 synthesis and/or IGF-I-mediated inhibition of IGFBP-3 proteolysis with a subsequently decreased generation of proteolytic fragments accompanied by down-regulation of the IGF-IR provide mechanisms to guarantee a defined regulation of growth and proliferation.
Taken together, these observations point to a complex regulatory system, involving both positive and negative feedback mechanisms. Dissecting the role and physiological significance of the individual components of this system is essential to an understanding of the IGF axis in malignant disease. The regulation of the individual components of the IGF axis by exposure to IGF-I suggests a model in which these growth factors may be able to autoregulate their interaction with cellsurface binding sites.
